Granted Patent B2

US 12,522,802 · App. 18/643,778 · Granted Jan 13, 2026

Inventors: Doris A Taylor (St. Paul, MN); Stefan M. Kren (Minneapolis, MN)

Assignee: Miromatrix Medical Inc.

C12N5/0062A61L27/3604A61L27/3808

Abstract

Claims (24)

1 . An ex vivo method of reendothelializing a decellularized mammalian tissue or organ matrix, comprising:

perfusing a perfusion decellularized mammalian vascularized tissue or organ matrix antegrade and retrograde with a physiological composition comprising a substantially pure population of endothelial cells or endothelial progenitor cells, wherein the reendothelialization of the perfusion decellularized vascularized mammalian tissue or organ matrix is enhanced relative to the reendothelialization of a corresponding perfusion decellularized vascularized mammalian tissue or organ matrix after perfusing a composition having the same number of cells antegrade or retrograde.

2 . The method of claim 1 wherein the endothelial cells are selected from the group consisting of blood endothelial cells, bone marrow endothelial cells, circulating endothelial cells, human aorta endothelial cells, human brain microvascular endothelial cells, human dermal microvascular endothelial cells, human intestinal microvascular endothelial cells, human lung microvascular endothelial cells, human microvascular endothelial cells, hepatic sinusoidal endothelial cells, human saphenous vein endothelial cells, human umbilical vein endothelial cells, lymphatic endothelial cells, microvessel endothelial cells, microvascular endothelial cells, pulmonary artery endothelial cells, retinal capillary endothelial cells, retinal microvascular endothelial cells, vascular endothelial cells, umbilical cord blood endothelial cells, liver sinusoidal endothelial cells, colony forming unit-endothelial cells (CFU-ECs), circulating angiogenic cells (CACs), circulating endothelial precursors (CEPs), endothelial colony-forming cells (ECFC), low proliferative potential ECFC (LPP-ECFC), high proliferative ECFC (HPP-ECFC), and combinations thereof.

3 . The method of claim 1 wherein the endothelial cells or endothelial progenitor cells are embryonic stem cells (ESCs)- or induced pluripotent stem cells (iPSCs)-derived endothelial cells or endothelial progenitor cells.

4 . The method of claim 1 wherein the tissue or organ matrix originates from an organ selected from a heart, kidney, liver, lung, pancreas, intestine, muscle, skin, breast, esophagus, trachea, or omentum.

5 . The method of claim 1 wherein the perfusion decellularized tissue or organ matrix and the endothelial cells or endothelial progenitor cells are xenogeneic.

6 . The method of claim 1 wherein the perfusion decellularized tissue or organ matrix and the endothelial cells or endothelial progenitor cells are allogeneic.

7 . The method of claim 1 further comprising introducing cells other than the endothelial or endothelial progenitor cells into or onto the tissue or organ matrix before perfusing the endothelial cells or the endothelial progenitor cells.

8 . The method of claim 1 further comprising introducing cells other than the endothelial or endothelial progenitor cells into or onto the tissue or organ matrix after perfusing the endothelial cells or the endothelial progenitor cells.

9 . A method of reducing thrombogenesis and immunogenicity in a recellularized tissue or organ following transplantation into a recipient, comprising:

a) perfusing a perfusion decellularized mammalian vascularized tissue or organ matrix antegrade and retrograde with a physiological composition comprising a substantially pure population of endothelial cells or endothelial progenitor cells, wherein the reendothelialization of the perfusion decellularized vascularized mammalian tissue or organ matrix is enhanced relative to the reendothelialization of a corresponding perfusion decellularized vascularized mammalian tissue or organ matrix after perfusing a composition having the same number of cells antegrade or retrograde; and

b) transplanting the reendothelialized tissue or organ matrix into the recipient.

10 . The method of claim 9 wherein the endothelial cells are selected from the group consisting of blood endothelial cells, bone marrow endothelial cells, circulating endothelial cells, human aorta endothelial cells, human brain microvascular endothelial cells, human dermal microvascular endothelial cells, human intestinal microvascular endothelial cells, human lung microvascular endothelial cells, human microvascular endothelial cells, hepatic sinusoidal endothelial cells, human saphenous vein endothelial cells, human umbilical vein endothelial cells, lymphatic endothelial cells, microvessel endothelial cells, microvascular endothelial cells, pulmonary artery endothelial cells, retinal capillary endothelial cells, retinal microvascular endothelial cells, vascular endothelial cells, umbilical cord blood endothelial cells, liver sinusoidal endothelial cells, colony forming unit-endothelial cells (CFU-ECs), circulating angiogenic cells (CACs), circulating endothelial precursors (CEPs), endothelial colony-forming cells (ECFC), low proliferative potential ECFC (LPP-ECFC), high proliferative ECFC (HPP-ECFC), and combinations thereof.

11 . The method of claim 9 wherein the endothelial cells or endothelial progenitor cells are embryonic stem cells (ESCs)- or induced pluripotent stem cells (iPSCs)-derived endothelial cells or endothelial progenitor cells.

12 . The method of claim 9 wherein the tissue or organ matrix originates from an organ selected from a heart, kidney, liver, lung, pancreas, intestine, muscle, skin, breast, esophagus, trachea, or omentum.

13 . The method of claim 9 wherein the perfusion decellularized tissue or organ matrix and the endothelial cells or endothelial progenitor cells are xenogeneic.

14 . The method of claim 9 wherein the perfusion decellularized tissue or organ matrix and the endothelial cells or endothelial progenitor cells are allogeneic.

15 . The method of claim 9 wherein the perfusion decellularized tissue or organ matrix is xenogeneic to the recipient and wherein the endothelial cells or endothelial progenitor cells are allogeneic to the recipient.

16 . The method of claim 9 further comprising introducing a second physiological composition comprising cells other than the endothelial or endothelial progenitor cells into or onto the tissue or organ matrix before step a).

17 . The method of claim 9 further comprising introducing cells other than the endothelial or endothelial progenitor cells into or onto the tissue or organ matrix after step a) and before step b).

18 . The method of claim 9 further comprising introducing cells other than the endothelial cells or endothelial progenitor cells into or onto the tissue or organ matrix after step b).

19 . The method of claim 16 wherein the second physiological composition comprising cells other than the endothelial cells or endothelial progenitor cells is introduced to the tissue or organ matrix via perfusion, direct injection, topical application, or combinations thereof.

20 . An ex vivo method of reendothelializing a decellularized kidney, liver, lung, or pancreas matrix of a mammal, comprising:

perfusing a perfusion decellularized mammalian vascularized kidney, liver, lung, or pancreas matrix antegrade and retrograde with a physiological composition comprising a substantially pure population of endothelial cells or endothelial progenitor cells, wherein the reendothelialization of the perfusion decellularized vascularized mammalian kidney, liver, lung, or pancreas matrix is enhanced relative to the reendothelialization of a corresponding perfusion decellularized vascularized mammalian tissue or organ matrix after perfusing a composition having the same number of cells antegrade or retrograde.

Assignments (1)

Continuity (5)

References Cited (33)